These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 679597)

  • 1. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.
    Rane A; Villeneuve JP; Stone WJ; Nies AS; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1978 Aug; 24(2):199-207. PubMed ID: 679597
    [No Abstract]   [Full Text] [Related]  

  • 2. [Impaired plasma protein binding of furosemide in nephrotic syndrome and uremia].
    Takahashi F
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):665-80. PubMed ID: 7176178
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.
    González-Martín G; Bravo I; Ibarra N; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):598-601. PubMed ID: 6668097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies.
    Keller F
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S24-6. PubMed ID: 7781201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of furosemide delivery to its site of action.
    Sjöström PA; Kron BG; Odlind BG
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
    Takamura N; Maruyama T; Otagiri M
    Clin Chem; 1997 Dec; 43(12):2274-80. PubMed ID: 9439444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of binding in distribution of furosemide: where is nonrenal clearance?
    Branch RA
    Fed Proc; 1983 Apr; 42(6):1699-702. PubMed ID: 6832389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and diuretic effect of furosemide in the nephrotic syndrome.
    Keller E; Hoppe-Seyler G; Schollmeyer P
    Clin Pharmacol Ther; 1982 Oct; 32(4):442-9. PubMed ID: 7116760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and response to bumetanide and furosemide.
    Brater DC
    Am J Cardiol; 1986 Jan; 57(2):20A-25A. PubMed ID: 3511654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furosemide binding to human albumin and plasma of nephrotic children.
    Prandota J; Pruitt AW
    Clin Pharmacol Ther; 1975 Feb; 17(2):159-65. PubMed ID: 235396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
    Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M
    Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia.
    Waldmann TA; Strober W; Mogielnicki RP
    J Clin Invest; 1972 Aug; 51(8):2162-74. PubMed ID: 5054468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced in vitro binding of tryptophan by plasma in uremia.
    de Torrente A; Glazer GB; Gulyassy P
    Kidney Int; 1974 Oct; 6(4):222-9. PubMed ID: 4427418
    [No Abstract]   [Full Text] [Related]  

  • 14. Biophysical insight into furosemide binding to human serum albumin: a study to unveil its impaired albumin binding in uremia.
    Zaidi N; Ahmad E; Rehan M; Rabbani G; Ajmal MR; Zaidi Y; Subbarao N; Khan RH
    J Phys Chem B; 2013 Mar; 117(9):2595-604. PubMed ID: 23438181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levels of plasma proteins in patients with ene stage renal failure treated with peritoneal dialysis with an addition of furosemide to dialysis fluid].
    Grzegorzewska A; Krzymański M; Antoniewicz K
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):137-40. PubMed ID: 8090666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of orally administered furosemide in children with nephrotic syndrome].
    Prandota J
    Pediatr Pol; 1982; 57(9):711-8. PubMed ID: 7170150
    [No Abstract]   [Full Text] [Related]  

  • 18. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.
    Odar-Cederlöf I; Borgå O
    Eur J Clin Pharmacol; 1974; 7(1):31-7. PubMed ID: 4852619
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowered protein content of tissue fluid in patients with the nephrotic syndrome: observations during disease and recovery.
    Koomans HA; Kortlandt W; Geers AB; Dorhout Mees EJ
    Nephron; 1985; 40(4):391-5. PubMed ID: 4022206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of furosemide in advanced renal failure.
    Huang CM; Atkinson AJ; Levin M; Levin NW; Quintanilla A
    Clin Pharmacol Ther; 1974 Oct; 16(4):659-66. PubMed ID: 4422027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.